Notably, in a large-scale cohort involving Chinese lung cancer patients, six of twelve patients with NTRK1 fusion-positive NSCLC had co-occurring EGFR mutations and were previously treated with EGFR-TKIs, suggesting that NTRK1 fusions were the potential resistance mechanisms to EGFR-TKIs regardless of its generation (28). The gene discussed is NTRK1; the disease is non-small cell lung carcinoma.